Christine Lovly: Striving to overcome MRD observed with Targeted Therapy in Lung Cancer
Christine Lovly, Associate Professor of Medicine with tenure at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, reshared a post by Break Through Cancer on X, adding:
“Tackling big problems requires radical collaboration .
The “PoweRD 2 Cure” team strives to overcome minimal residual disease (MRD) observed with targeted therapy in lung cancer.
Powerhouse team to conquer an urgent, unmet clinical question.”
Quoting Break Through Cancer‘s post:
“Today we launch the PoweRD 2 Cure ALK+ Lung Cancer TeamLab!
Uniting researchers from Dana-Farber, MD Anderson Cancer Center, Koch Institute at MIT, Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Boston Children’s, Mass General Cancer Center, CU Cancer Center and Vanderbilt-Ingram Cancer Center in radical collaboration to target residual lung cancer cells remaining after initial therapy.
Read more.”
Christine M. Lovly is an associate professor of medicine with tenure at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center. Dr. Lovly is also an elected member of the American Society for Clinical Investigation (ASCI) and a member of the Editorial Board for Cancer Discovery and JCO Precision Oncology. She is a member of the Board of the American Association for Cancer Research. She serves on the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer Research (where she also serves as SLB director), the LUNGevity Foundation, and the Lung Cancer Research Foundation. She is co-director of the AACR Molecular Biology in Clinical Oncology course and serves on the AACR Science Policy and Government Affairs committee. In 2021, she was awarded the ECOG-ACRIN Cancer Research Group Young Investigator Award. Dr. Lovly is the co-Editor-in-Chief for My Cancer Genome
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023